Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor cell vaccine-Hoag Memorial Hospital Presbyterian-melanoma
- Development stage
- Unknown
- Lead developer
- Hoag Memorial Hospital Presbyterian
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**Autologous tumor cell vaccine-Hoag Memorial Hospital Presbyterian-melanoma** is an individualized whole-tumor-cell cancer vaccine developed at Hoag Memorial Hospital Presbyterian for metastatic melanoma. It consists of irradiated melanoma cells expanded from a short-term tumor-cell line established using each patient's own metastatic melanoma tissue. The irradiated cells retain a patient-specific repertoire of melanoma tumor-associated antigens and are administered by subcutaneous injection to promote active antitumor immune responses. In the MAC-VAC randomized Phase II study, the vaccine was administered with granulocyte-macrophage colony-stimulating factor as an immune adjuvant and compared with the autologous dendritic-cell vaccine melapuldencel-T.
- Other names
- autologous tumor cell vaccine
Beyond the preview
Go deeper on autologous tumor cell vaccine-Hoag Memorial Hospital Presbyterian-melanoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor cell vaccine-Hoag Memorial Hospital Presbyterian-melanoma.